TERN-800
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 08, 2023
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates
(GlobeNewswire)
- "TERN-800: Oral, small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity...Candidate nomination and initiation of IND-enabling activities expected in 2024."
Preclinical • Metabolic Disorders • Obesity
1 to 1
Of
1
Go to page
1